TOVX Theriva Biologics Inc

Price (delayed)

$0.2623

Market cap

$4.53M

P/E Ratio

N/A

Dividend/share

N/A

EPS

-$1.16

Enterprise value

-$11.81M

Synthetic Biologics, Inc. is a diversified clinical-stage company leveraging the microbiome to develop therapeutics designed to prevent and treat gastrointestinal (GI) diseases in areas of high unmet need. The Company's ...

Highlights
The debt has declined by 18% year-on-year and by 6% since the previous quarter
Theriva Biologics's EPS has increased by 12% YoY
The net income has increased by 4.3% YoY but it has decreased by 3.7% QoQ
TOVX's equity is down by 34% YoY and by 15% from the previous quarter
The quick ratio has decreased by 27% YoY and by 11% from the previous quarter

Key stats

What are the main financial stats of TOVX
Market
Shares outstanding
17.28M
Market cap
$4.53M
Enterprise value
-$11.81M
Valuations
Price to earnings (P/E)
N/A
Price to book (P/B)
0.14
Price to sales (P/S)
N/A
EV/EBIT
N/A
EV/EBITDA
N/A
EV/Sales
N/A
Earnings
Revenue
$0
EBIT
-$20.35M
EBITDA
-$19.71M
Free cash flow
-$18.46M
Per share
EPS
-$1.16
Free cash flow per share
-$1.08
Book value per share
$1.83
Revenue per share
$0
TBVPS
$2.52
Balance sheet
Total assets
$48.73M
Total liabilities
$14.61M
Debt
$2.02M
Equity
$31.39M
Working capital
$15.65M
Liquidity
Debt to equity
0.06
Current ratio
3.6
Quick ratio
3.06
Net debt/EBITDA
0.83
Margins
EBITDA margin
N/A
Gross margin
N/A
Net margin
N/A
Operating margin
N/A
Efficiency
Return on assets
-33%
Return on equity
-49.3%
Return on invested capital
-102.4%
Return on capital employed
-47.6%
Return on sales
N/A
Dividend
Dividend yield
N/A
DPS
N/A
Payout ratio
N/A

TOVX stock price

How has the Theriva Biologics stock price performed over time
Intraday
0.88%
1 week
4.92%
1 month
0.88%
1 year
-62.53%
YTD
-39.01%
QTD
9.29%

Financial performance

How have Theriva Biologics's revenue and profit performed over time
Revenue
$0
Gross profit
$0
Operating income
-$21.65M
Net income
-$19.04M
Gross margin
N/A
Net margin
N/A
The net income has increased by 4.3% YoY but it has decreased by 3.7% QoQ
The company's operating income rose by 3.8% YoY

Growth

What is Theriva Biologics's growth rate over time

Valuation

What is Theriva Biologics stock price valuation
P/E
N/A
P/B
0.14
P/S
N/A
EV/EBIT
N/A
EV/EBITDA
N/A
EV/Sales
N/A
Theriva Biologics's EPS has increased by 12% YoY
TOVX's P/B is 53% below its last 4 quarters average of 0.3
TOVX's equity is down by 34% YoY and by 15% from the previous quarter

Efficiency

How efficient is Theriva Biologics business performance
The ROE is down by 32% YoY and by 15% QoQ
The return on invested capital is up by 24% year-on-year
The ROA has contracted by 23% YoY and by 13% from the previous quarter

Dividends

What is TOVX's dividend
DPS
N/A
Dividend yield
N/A
Payout ratio
N/A

There are no recent dividends present for TOVX.

Financial health

How did Theriva Biologics financials performed over time
The total assets has contracted by 28% YoY and by 12% from the previous quarter
The quick ratio has decreased by 27% YoY and by 11% from the previous quarter
The debt is 94% smaller than the equity
TOVX's equity is down by 34% YoY and by 15% from the previous quarter
The debt to equity has grown by 20% YoY

All financial data is based on trailing twelve months (TTM) periods - updated quarterly, unless otherwise specified.